MRI Radiomics and Machine Learning for the Prediction of Oncotype Dx Recurrence Score in Invasive Breast Cancer

被引:11
|
作者
Romeo, Valeria [1 ]
Cuocolo, Renato [2 ,3 ]
Sanduzzi, Luca [1 ]
Carpentiero, Vincenzo [1 ]
Caruso, Martina [1 ]
Lama, Beatrice [1 ]
Garifalos, Dimitri [1 ]
Stanzione, Arnaldo [1 ]
Maurea, Simone [1 ]
Brunetti, Arturo [1 ]
机构
[1] Univ Naples Federico II, Dept Adv Biomed Sci, I-80131 Naples, Italy
[2] Univ Salerno, Dept Med Surg & Dent, I-84084 Baronissi, Italy
[3] Univ Naples Federico II, Dept Elect Engn & Informat Technol, Augmented Real Hlth Monitoring Lab ARHeMLab, I-80131 Naples, Italy
关键词
radiomics; oncotype DX; breast cancer; machine learning; neoadjuvant chemotherapy; magnetic resonance; recurrence score; CHEMOTHERAPY; TAMOXIFEN; FEATURES; RISK;
D O I
10.3390/cancers15061840
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary The preoperative definition of the Oncotype DX recurrence score would be critical to identify breast cancer patients who could benefit from chemotherapy before surgery. In this work, we built a machine learning model applied to DCE-MRI images of a publicly available dataset to predict the Oncotype DX score in patients with breast cancer. As a result, the model achieved an accuracy of 60% in the training set and 63% (AUC = 0.66) in the test set. Our findings support the feasibility of radiomics and machine learning for the prediction of prognostic data in breast cancer, encouraging further, preferably multicenter, investigations to further improve the performance of the model and assess its generalizability. Aim: To non-invasively predict Oncotype DX recurrence scores (ODXRS) in patients with ER+ HER2- invasive breast cancer (IBC) using dynamic contrast-enhanced (DCE) MRI-derived radiomics features extracted from primary tumor lesions and a ML algorithm. Materials and Methods: Pre-operative DCE-MRI of patients with IBC, no history of neoadjuvant therapy prior to MRI, and for which the ODXRS was available, were retrospectively selected from a public dataset. ODXRS was obtained on histological tumor samples and considered as positive if greater than 16 and 26 in patients aged under and over 50 years, respectively. Tumor lesions were manually annotated by three independent operators on DCE-MRI images through 3D ROIs positioning. Radiomic features were therefore extracted and selected using multistep feature selection process. A logistic regression ML classifier was then employed for the prediction of ODXRS. Results: 248 patients were included, of which 87 with positive ODXRS. 166 (66%) patients were grouped in the training set, while 82 (33%) in the test set. A total of 1288 features was extracted. Of these, 1244 were excluded as 771, 82 and 391 were excluded as not stable (n = 771), not variant (n = 82), and highly intercorrelated (n = 391), respectively. After the use of recursive feature elimination with logistic regression estimator and polynomial transformation, 92 features were finally selected. In the training set, the logistic regression classifier obtained an overall mean accuracy of 60%. In the test set, the accuracy of the ML classifier was 63%, with a sensitivity of 80%, specificity of 43%, and AUC of 66%. Conclusions: Radiomics and ML applied to pre-operative DCE-MRI in patients with IBC showed promises for the non-invasive prediction of ODXRS, aiding in selecting patients who will benefit from NAC.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Comparison of DCIS Recurrence Risk Prediction Models: MSK Breast Cancer Nomogram and the Oncotype DX DCIS Score
    Fineberg, Susan
    DiDonato, Rosemarie
    Fox, Jana
    Lo, Yungtai
    Makower, Della
    MODERN PATHOLOGY, 2018, 31 : 60 - 60
  • [22] Comparison of DCIS Recurrence Risk Prediction Models: MSK Breast Cancer Nomogram and the Oncotype DX DCIS Score
    Fineberg, Susan
    DiDonato, Rosemarie
    Fox, Jana
    Lo, Yungtai
    Makower, Della
    LABORATORY INVESTIGATION, 2018, 98 : 60 - 60
  • [23] Using Machine Learning to Predict Oncotype DX Risk-of-Recurrence Categories in EarlyStage Breast Cancer
    Enwere, Emeka
    Bigras, Gilbert
    Beyer, David
    LABORATORY INVESTIGATION, 2024, 104 (03) : S1566 - S1566
  • [24] Prediction of response to neoadjuvant chemotherapy in ER plus breast cancer: Magee equation recurrence versus oncotype DX® recurrence score
    Soran, A.
    Johnson, R.
    Menekse, E.
    Bhargava, R.
    McGuire, K.
    McAuliffe, P.
    Ahrendt, G.
    Dabbs, D.
    Bonaventura, M.
    CANCER RESEARCH, 2016, 76
  • [25] Oncotype DX recurrence score implications for disparities in chemotherapy and breast cancer mortality in Georgia
    Lindsay J. Collin
    Ming Yan
    Renjian Jiang
    Kevin C. Ward
    Brittany Crawford
    Mylin A. Torres
    Keerthi Gogineni
    Preeti D. Subhedar
    Samantha Puvanesarajah
    Mia M. Gaudet
    Lauren E. McCullough
    npj Breast Cancer, 5
  • [26] Clinical Impact of a Novel Model Predictive of Oncotype DX Recurrence Score in Breast Cancer
    Yamamoto, Shinya
    Chishima, Takashi
    Shibata, Yukako
    Harada, Fumi
    Takeuchi, Hideki
    Yamada, Akimitsu
    Narui, Kazutaka
    Misumi, Toshihiro
    Ishikawa, Takashi
    Endo, Itaru
    IN VIVO, 2021, 35 (04): : 2439 - 2444
  • [27] Oncotype DX recurrence score implications for disparities in chemotherapy and breast cancer mortality in Georgia
    Collin, Lindsay J.
    Yan, Ming
    Jiang, Renjian
    Ward, Kevin C.
    Crawford, Brittany
    Torres, Mylin A.
    Gogineni, Keerthi
    Subhedar, Preeti D.
    Puvanesarajah, Samantha
    Gaudet, Mia M.
    McCullough, Lauren E.
    NPJ BREAST CANCER, 2019, 5 (1)
  • [28] Proposed criteria for luminal A breast cancer accurately predict Oncotype dx™ recurrence score
    Heinemann, F. S.
    BREAST, 2015, 24 : S116 - S116
  • [29] Breast cancer histopathology is predictive of low-risk Oncotype Dx recurrence score
    Wilson, Parker C.
    Chagpar, Anees B.
    Cicek, Ali F.
    Bossuyt, Veerle
    Buza, Natalia
    Mougalian, Sarah
    Killelea, Brigid K.
    Patel, Natalie
    Harigopal, Malini
    BREAST JOURNAL, 2018, 24 (06): : 976 - 980
  • [30] Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results
    Kamaljeet Singh
    Xin He
    Elizabeth T. Kalife
    Shahrzad Ehdaivand
    Yihong Wang
    C. James Sung
    Breast Cancer Research and Treatment, 2018, 168 : 29 - 34